Guggenheim Forecasts Strong Price Appreciation for Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics (NASDAQ:TNGX) had its target price raised by analysts at Guggenheim from $18.00 to $20.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 17.99% from the company’s current price.

A number of other equities analysts have also issued reports on TNGX. HC Wainwright raised their target price on Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a research report on Friday. Mizuho assumed coverage on Tango Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $19.00 price target for the company. B. Riley Financial raised their price target on Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Stifel Nicolaus assumed coverage on shares of Tango Therapeutics in a report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Tango Therapeutics Stock Up 0.7%

Tango Therapeutics stock opened at $16.95 on Friday. The firm has a 50-day moving average price of $11.86 and a two-hundred day moving average price of $9.46. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $17.63.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 66.01%. Research analysts expect that Tango Therapeutics will post -1.19 earnings per share for the current year.

Insider Activity

In other Tango Therapeutics news, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares in the company, valued at approximately $2,259,481.22. The trade was a 5.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the completion of the sale, the director directly owned 1,629,254 shares of the company’s stock, valued at $19,974,654.04. The trade was a 1.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 113,633 shares of company stock worth $1,420,857 over the last 90 days. 7.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. lifted its stake in Tango Therapeutics by 138.8% during the first quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock valued at $97,000 after purchasing an additional 40,983 shares during the last quarter. AQR Capital Management LLC acquired a new position in Tango Therapeutics in the first quarter worth approximately $195,000. Dynamic Technology Lab Private Ltd increased its holdings in shares of Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after buying an additional 15,037 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Tango Therapeutics by 28.3% in the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock valued at $693,000 after buying an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Tango Therapeutics by 270.6% during the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock valued at $483,000 after acquiring an additional 257,668 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

More Tango Therapeutics News

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.